Kara L Davis
Overview
Explore the profile of Kara L Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
6596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Aftandilian C, Bito X, Berman D, Zhang A, Duttagupta R, Davis K
Eur J Haematol
. 2024 Apr;
113(2):208-217.
PMID: 38658354
Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (R/R B ALL). Cytokine release syndrome (CRS)...
12.
Schultz L, Jeyakumar N, Kramer A, Sahaf B, Srinagesh H, Shiraz P, et al.
Leukemia
. 2024 Mar;
38(5):963-968.
PMID: 38491306
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22 malignancies with progression after CD19-directed therapies. Using on-site, automated, closed-loop manufacturing, we conducted...
13.
Klysz D, Fowler C, Malipatlolla M, Stuani L, Freitas K, Chen Y, et al.
Cancer Cell
. 2024 Jan;
42(2):266-282.e8.
PMID: 38278150
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8 CAR-T cells express CD39 and CD73, which mediate proximal steps in Ado generation. Here, we sought to enhance...
14.
Shyr D, Davis K, Bertaina A
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):84-90.
PMID: 38066901
Hematopoietic stem cell transplantation (HSCT) represents a consolidated therapeutic strategy for high-risk pediatric acute lymphoblastic leukemia (ALL), offering the potential for curative treatment. This manuscript delves into the debate around...
15.
Pan F, Sarno J, Jeong J, Yang X, Jager A, Gruber T, et al.
J Clin Invest
. 2023 Nov;
134(1).
PMID: 37917159
A t(4;11) leukemia model established from CRISPR-engineered chromosomal translocations between the KMT2A and AFF1 genes recapitulate proteomic, epigenomic, and transcriptomic features of primary patient leukemias.
16.
Ligon J, Ramakrishna S, Ceppi F, Calkoen F, Diorio C, Davis K, et al.
Transplant Cell Ther
. 2023 Oct;
30(2):155-170.
PMID: 37863355
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell malignancies, with multiple CAR T cell products approved for numerous indications by regulatory agencies worldwide. However,...
17.
Koladiya A, Davis K
Clin Lab Med
. 2023 Jul;
43(3):507-519.
PMID: 37481326
The advent of high-dimensional single-cell technologies has enabled detection of cellular heterogeneity and functional diversity of immune cells during health and disease conditions. Because of its multiplexing capabilities and limited...
18.
Keyes T, Koladiya A, Lo Y, Nolan G, Davis K
Bioinform Adv
. 2023 Jun;
3(1):vbad071.
PMID: 37351311
Summary: While many algorithms for analyzing high-dimensional cytometry data have now been developed, the software implementations of these algorithms remain highly customized-this means that exploring a dataset requires users to...
19.
Sarno J, Domizi P, Liu Y, Merchant M, Pedersen C, Jedoui D, et al.
Nat Commun
. 2023 May;
14(1):2935.
PMID: 37217509
Resistance to glucocorticoids (GC) is associated with an increased risk of relapse in B-cell progenitor acute lymphoblastic leukemia (BCP-ALL). Performing transcriptomic and single-cell proteomic studies in healthy B-cell progenitors, we...
20.
Klysz D, Fowler C, Malipatlolla M, Stuani L, Freitas K, Meier S, et al.
bioRxiv
. 2023 May;
PMID: 37162847
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8 CAR T cells mediate Ado-induced immunosuppression through CD39/73-dependent Ado production. Knockout of CD39, CD73 or A2aR had modest...